Skip to main content

CORRECTION article

Front. Cell. Infect. Microbiol., 26 August 2022
Sec. Clinical Microbiology
Volume 12 - 2022 | https://doi.org/10.3389/fcimb.2022.1006226

Corrigendum: Advancement in the development of therapeutics against Zika virus infection

This article is a correction to:

  1. Advancement in the Development of Therapeutics Against Zika Virus Infection

    1. Read original article
Kangchen LiKangchen Li1Qianting JiQianting Ji1Shibo Jiang*Shibo Jiang2*Naru Zhang*Naru Zhang1*
  • 1Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China
  • 2Key Laboratory of Medical Molecular Virology of Ministry of Education (MOE), National Health Commission (NHC) and Chinese Academy of Medical Sciences (CAMS), School of Basic Medical Sciences and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

A corrigendum on
Advancement in the development of therapeutics against zika virus infection

by Li K, Ji Q, Jiang S, and Zhang N (2022). Front. Cell. Infect. Microbiol. 12:946957. doi: 10.3389/fcimb.2022.946957

Text Correction

In the published article, there was an error. [There is a spelling mistake by writing “NS5 protease inhibitors” in key words on page 1 and in one of the subheadings named “NS5 Protease Inhibitors” on page 4].

A correction has been made to [“Key words” and “THE DEVELOPMENT OF ANTI-ZIKV THERAPEUTICS”], [NS5 Protease Inhibitors], [the subheading of “NS5 Protease Inhibitors”]. This sentence previously stated: “[NS5 Protease Inhibitors]”

The corrected sentence appears below: “[NS5 Protein Inhibitors]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Zika virus, pathogenesis, therapeutics, NS2B–NS3 protease inhibitors, NS3 protease inhibitors, NS5 protein inhibitors, E protein inhibitors, host protein inhibitors

Citation: Li K, Ji Q, Jiang S and Zhang N (2022) Corrigendum: Advancement in the development of therapeutics against Zika virus infection. Front. Cell. Infect. Microbiol. 12:1006226. doi: 10.3389/fcimb.2022.1006226

Received: 29 July 2022; Accepted: 03 August 2022;
Published: 26 August 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Ji, Jiang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shibo Jiang, shibojiang@fudan.edu.cn; Naru Zhang, zhangnr@zucc.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.